Schweizerischer Nationalfonds / Fonds national suisse
Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence
mehr
Storys zum Thema Medikament
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression
London (ots/PRNewswire) - COMPASS Pathways (https://compasspathways.com/), a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for ...
mehrNew Phase 2 Data Show Stelara® (ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year
Beerse, Belgium (ots/PRNewswire) - - Janssen presents one-year data from continued Phase 2 lupus study during plenary session at 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
mehrMerck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt
Darmstadt, Germany (ots/PRNewswire) - - Expansion of the pharma manufacturing site at Merck's headquarters supports growth of current and future portfolio of pharma medicines - New building dedicated to the packaging and shipping of Merck's pharma medicines in more than 90 countries - EUR63 million investment in new packaging center is part of wider EUR1 billion ...
mehrJanssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology
Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...
mehrBAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
mehr
flutiform® k-haler®, a Novel Treatment for Adolescents and Adults With Asthma, Now Available in Europe
Cambridge, England (ots/PRNewswire) - - flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older)[1] - Research indicates that many patients make errors with their inhalers and this is associated with poor asthma control and increased exacerbations[2] - ...
mehrOzempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline
Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...
mehrCOMPASS Pathways Receives FDA Approval for Psilocybin Therapy Clinical Trial for Treatment-resistant Depression
London (ots/PRNewswire) - COMPASS Pathways (https://compasspathways.com/), a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for ...
mehrKyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
Tokyo (ots/PRNewswire) - - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in previously treated patients based on data showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat. - FDA approval was based ...
mehrNew Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
A novel antibiotic from weeds
Researchers working on an SNSF project have discovered novel, antibiotically active chemical substances in a previously rarely explored site: the leaf of a common field weed. The just published findings show that this microcosm contains many still unknown natural products that could lead to new drugs. Many of the antibiotics used today were developed from natural products made by ...
mehr
Merck Receives Recommendation for Approval in 21 EU Countries for the New Formulation of Euthyrox®
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - German Federal Institute for Drugs and Medical Devices (BfArM) recommends new formulation of Euthyrox® for approval in 21 EU countries - BfArM is acting as a representative of all 21 EU countries involved in the EU worksharing procedure Merck, a leading science and technology company, today ...
mehrMerck Launches Online Platform Fertility.com
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Fertility.com is the gateway to two online portals: - Offering the latest scientific information to healthcare professionals in the advancing field of fertility - Supporting women, men and couples who are looking for information about fertility and/or undergoing fertility treatment (Photo: ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Cancer: More targeted use of immunotherapy
Doctors are increasingly fighting cancer by stimulating patients' immune systems. SNSF-supported researchers have now discovered a method for predicting the likelihood of treatment success. Immunotherapy changes a patient's immune system to allow it to attack cancer cells and either destroy them or at least keep them from growing. ...
mehr
Vorherige6789101112131415